Novel obesity drug induces up to 22% weight loss with no safety concerns
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a significant weight reduction compared with placebo, according to top-line results from a phase 1b/2a trial.
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...
If your constipation lasts for more than 3 days, speak with your doctor about options to help. You might need to add a stool ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback